Phenotypic characterization of T cells from AML patients. (A) FACS analysis of T cell phenotype in AML patients (n=21), adult (below 30 years; n=5) and aged matched (senior; n=5) healthy donors. T cell subpopulations within CD4+ and CD8+ cells are depicted. TN: naïve; TSCM: stem central memory; TCM: central memory; TEM: effector memory; TE: effector. (B) Percentage of Naïve (left) and effector (right) T cell subpopulations in CD8+ T cells from AML patients (n=21), adult (n=5) and senior (n=5) healthy donors. (C) Analysis of the expression of CD69, HLA-DR, PD1 and LAG3 in CD8+ T cells from AML patients (n=21), adult (n=5) and senior (n=5) healthy donors. Mean ± SEM for each group is depicted. Kruskal-Wallis test with Dunn’s multiple comparisons test. ns, not significant; *p<0.05; **p<0.01; ***p<0.001. Phenotypic characterization of CD33-CAR-T cells from AML patients. (A) Population doublings of CAR-T cells generated from AML patients (n=7), adult (n=5) and senior (n=5) healthy donors during CAR-T cell production. (B) Percentage of transduced cells (CAR+) at the end of each CAR-T cell production. (C) Analysis of the phenotype of CAR-T cells at resting state for each group. CAR-T cell subpopulations within CD4+ and CD8+ cells are depicted. TN, naïve; TSCM, stem central memory; TCM, central memory; TEM, effector memory; TE, effector. (D) Analysis of the expression of CD69, HLA-DR, PD1 and LAG3 in CD8+ T cells from AML patients (n=7), adult (n=5) and senior (n=5) healthy donors. Mean ± SEM for each group is depicted. 2-way ANOVA with Tukey’s multiple comparisons test (A), Kruskal-Wallis test with Dunn’s multiple comparisons test (B, D). ns, not significant; *p<0.05; **p<0.01. Functional characterization of CD33-CAR-T cells from AML patients. (A) Quantification of the cytotoxic activity of CAR-T and UTD cells generated from AML patients (n=7), adult (n=5) and senior (n=5) healthy donors, against CD33+ (left) and CD33 knock-out (right) MOLM-13 AML cell line at different E:T ratio. The percentage of specific lysis for each CAR-T cell production is depicted. (B) Quantification of IFN-γ levels in supernatants from cytotoxic assays (ratio 1:3) measured by ELISA. The cytokine concentration (ng/ml) for each CAR-T cell production is depicted. Analysis of the expression of PD1 and LAG3 in CD4+
(C) and CD8+
(D) CAR-T cells from AML patients, adult, and senior healthy donors, before (basal) and after continuous repeated in vitro stimulation (reest) for 21 days with MOLM-13 tumoral cells. (E) Cytotoxic activity of CAR-T cells from AML patients (n=7), adult (n=5) and senior (n=5) healthy donors after continuous repeated in vitro stimulation for 21 days with MOLM-13 tumoral cells. (F) Survival of mice treated with CAR-T cells from AML patients, adult, and senior healthy donors. Untreated animals or treated with UTD cell form same groups were use as control. All groups included 12 animals (6 male and 6 female). Mean ± SEM of the average of three technical replicates for each group is depicted. Kruskal-Wallis test with Dunn’s multiple comparisons test (C, D), 2-way ANOVA with Tukey’s multiple comparisons test (E), Logrank test (F). ns, not significant; *p<0.05; **p<0.01; ***p<0.001. Transcriptomic characterization of CD33-CAR-T cells from AML patients. The transcriptomic landscape of CAR-T cells generated from AML patients (n=4), adult (n=3) and senior (n=3) healthy donors was profiled using high-throughput RNA sequencing (RNA-seq) (A) RNA-seq principal components (PC) analysis, corrected by patient heterogeneity, of sorted CD4+ and CD8+ CAR-T cell subsets. Percentage of variance explained by PC1 and PC2 are depicted. (B) Left: Heatmap of differentially expressed genes associated to stem cell memory and T cell activation shared between CD8+ CAR-T cells from AML patients and senior healthy donors (age-related) compared to adult CAR-T cells. Right: Quantification of CD28 and CIITA gene expression. (C) Left: Heatmap of differentially expressed genes specific for CD8+ CAR-T cells from AML patients (AML-specific) compared to adult and senior CAR-T cells. Right: Quantification of LAG3, NR4A1, CCR7 and OAS1 gene expression. (D) Quantification of CD81, CCL5, IRF1 and KLF2 gene expression as example of genes with disrupted expression pattern in AML CAR-T cells after stimulation with tumoral cells. Mean ± SEM for each group is depicted. Kruskal-Wallis test with Dunn’s multiple comparisons test (B, C), 2-way ANOVA with Tukey’s multiple comparisons test (D). ns, not significant; *p<0.05; **p<0.01; ***p<0.001. Characterization of HLA-IKO/TCRKO CD33-CAR-T cells. Selected CRISPR RNPs were combined with the Sleeping Beauty transposon system to generate HLA-IKO/TCRKO CD33-CAR-T (CAR-TKO) cells from healthy donors (n=8 independent samples) (A) Distribution of the different edited populations observed after simultaneous HLA-I and TCR targeting of CAR-T and UTD cells with CRISPR systems. (B) Percentage of transduced cells (CAR+) at the end of CAR-T and CAR-TKO cell production. (C) Percentage of HLA-IKO/TCRKO double negative cells in CAR-T and UTD cells before and after selection. (D) Percentage of transduced cells (CAR+) at the CAR-TKO cell production before and after selection of HLA-IKO/TCRKO double negative cells. (E) Population doublings of CAR-T and CAR-TKO cells during CAR-T cell production. UTD and UTDKO cells were use as control. (F) Analysis of CD4/CD8 ratio in CAR-T and CAR-TKO cells. (G) Analysis of the phenotype of CAR-T and CAR-TKO cells at resting state for each group. CAR-T cell subpopulations within CD4+ and CD8+ cells are depicted. TN, naïve; TSCM, stem central memory; TCM, central memory; TEM, effector memory; TE, effector. (H) Quantification of the cytotoxic activity of CAR-T and CAR-TKO cells against CD33+ MOLM-13 AML cell line at different E:T ratio. The percentage of specific lysis (average of three technical replicates) for each CAR-T cell production is depicted. UTD and UTDKO cells were used as control. (I) Survival of mice treated with CAR-T and CAR-TKO. Untreated animals or treated with UTD and UTDKO cells were used as control. Mean ± SEM for each group is depicted. Kruskal-Wallis test with Dunn’s multiple comparisons test (B, D), 2-way ANOVA with Tukey’s multiple comparisons test (E, H), Logrank test (I). ns, not significant; *p<0.05; ***p<0.001. Safety analysis of HLA-IKO/TCRKO CD33-CAR-T cells. (A) Analysis of the SB copy number integrations in CAR-T and CAR-TKO cells (n=8 independent productions). (B) Histogram plot showing the genomic annotation of SB integration sites in CAR-T and CAR-TKO cells (n=3 independent productions. (C) Sequences of cleavage sites identified by iGUIDE for B2M (left) and TRAC (right) sgRNAs annotated by on target or off target, with the total number of unique alignments associated with the site. Wilcoxon matched-pairs signed rank test (A). ns, not significant. Preclinical production of HLA-IKO/TCRKO CD33-CAR-T cells. (A) Percentage of HLA-IKO/TCRKO double negative cells before and after selection (n=3 independent productions). (B) Percentage of transduced cells (CAR+) at the CAR-TKO cell production after selection of HLA-IKO/TCRKO double negative cells (n=3 independent productions). (C) Population doublings of CAR-TKO cells during CAR-T cell production (n=3 independent productions). (D) Quantification of total number of CAR-TKO cells obtained at the end of the production after HLA-IKO/TCRKO double negative selection (n=3 independent productions). (E) Quantification of the cytotoxic activity of CAR-TKO cells against CD33+ MOLM-13 AML cell line at different E:T ratio. The percentage of specific lysis (average of three technical replicates) for each CAR-T cell productions (n=3) is depicted. (F) Quantification of IFN-γ levels in supernatants from cytotoxic assays (ratio 1:3) measured by ELISA. The cytokine concentration (ng/ml; average of three technical replicates) for each CAR-T cell production (n=3) is depicted. Mann Whitney test (B, C, F), 2-way ANOVA with Tukey’s multiple comparisons test (E). ns, not significant.